Medication info
Monarack 5 mg (Minoxidil)

Monarack 5 mg (Minoxidil)

Prescription medicationTablet
Ingredient · strength
Minoxidil›5mg / 1 tablet
Manufacturer / importer
Korea Prime Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 202503416 · Approved 2025.12.31

Summary

Main use
Treatment of refractory hypertension and hypertension with symptoms or target-organ damage
Who uses it
Adults · Children
Adult dosage
Adults (12 years and older): The initial dose is minoxidil 5㎎ orally once daily, with a maintenance dose of 10-40㎎ daily administered in 1 or divided doses. A maximum of 100㎎ may be administered per day. Dosing frequency: During treatment with this medicine, the extent of daily fluctuations in arterial blood pressure is proportional to the reduction in blood pressure. If the decrease in supine diastolic blood pressure is less than 30mmHg, it may be administered once daily; if the decrease is 30mmHg or greater, administer the daily dose in 2 divided doses. Dose adjustment: The dose should be determined carefully according to the patient's response. When adjusting the dose, allow an interval of at least 3 days, as an adequate response to the dose takes 3 days or longer to occur. If more rapid treatment of hypertension is required, the dose may be adjusted every 6 hours while the patient is carefully monitored. Concomitant administration Diuretics: This medicine is administered with a diuretic to patients whose salt and water balance depends on renal function. It has been administered concomitantly with the following diuretics: ① Hydrochlorothiazide (50㎎ per dose twice daily) or another thiazide diuretic (equivalent effective dose) ② Chlorthalidone (50-100㎎ per dose once daily) ③ Furosemide (40㎎ per dose twice daily) If excessive salt and water retention results in a weight gain of approximately 1.8㎏ or more, the diuretic should be changed to furosemide. If the patient is already receiving furosemide, increase the dose as needed. β-blockers or other sympatholytic agents: During treatment with this medicine, administer a β-blocker in divided doses equivalent to propranolol 80-160㎎ daily. If β-blockers are contraindicated, methyldopa (250-750㎎ per dose twice daily) may be administered instead. Because methyldopa takes time to exert its effect, administer it at least 24 hours before starting this medicine. Sympatholytic agents may not completely prevent the increase in heart rate caused by this medicine, but they can generally prevent tachycardia. Patients receiving a β-blocker before starting treatment with this medicine typically have bradycardia; however, their heart rate is expected to increase to normal with this medicine. Concomitant administration of this medicine with a β-blocker or other sympatholytic agent generally results in little change in heart rate because their opposing effects on the heart counteract each other. Adjust the dose as appropriate according to age and symptoms.
Children's dosage
Children (12 years and younger): The initial dose is 0.2㎎/kg of body weight once daily. The dose may be increased by 50-100% until blood pressure is optimally controlled. The maintenance dose is 0.25㎎-1.0㎎/kg of body weight daily. A maximum of 50㎎ may be administered per day.

Ingredients

Manufacturer
Korea Prime Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of refractory hypertension and hypertension with symptoms or target-organ damage

  • Hypertension
  • resistant hypertension
View approved original text

This medication is used to treat hypertension caused by secondary factors or target organ damage. It is also effective for resistant hypertension that does not respond to diuretics and two types of antihypertensives. In other words, it helps manage complex or hard-to-treat hypertension. Because of this characteristic, it contributes to improved blood pressure control, thereby reducing the risk of cardiovascular diseases. As such, it is widely used in the treatment of hypertension.

Dosage and Administration

Adult dosage

Adults (12 years and older): The initial dose is minoxidil 5㎎ orally once daily, with a maintenance dose of 10-40㎎ daily administered in 1 or divided doses. A maximum of 100㎎ may be administered per day. Dosing frequency: During treatment with this medicine, the extent of daily fluctuations in arterial blood pressure is proportional to the reduction in blood pressure. If the decrease in supine diastolic blood pressure is less than 30mmHg, it may be administered once daily; if the decrease is 30mmHg or greater, administer the daily dose in 2 divided doses. Dose adjustment: The dose should be determined carefully according to the patient's response. When adjusting the dose, allow an interval of at least 3 days, as an adequate response to the dose takes 3 days or longer to occur. If more rapid treatment of hypertension is required, the dose may be adjusted every 6 hours while the patient is carefully monitored. Concomitant administration Diuretics: This medicine is administered with a diuretic to patients whose salt and water balance depends on renal function. It has been administered concomitantly with the following diuretics: ① Hydrochlorothiazide (50㎎ per dose twice daily) or another thiazide diuretic (equivalent effective dose) ② Chlorthalidone (50-100㎎ per dose once daily) ③ Furosemide (40㎎ per dose twice daily) If excessive salt and water retention results in a weight gain of approximately 1.8㎏ or more, the diuretic should be changed to furosemide. If the patient is already receiving furosemide, increase the dose as needed. β-blockers or other sympatholytic agents: During treatment with this medicine, administer a β-blocker in divided doses equivalent to propranolol 80-160㎎ daily. If β-blockers are contraindicated, methyldopa (250-750㎎ per dose twice daily) may be administered instead. Because methyldopa takes time to exert its effect, administer it at least 24 hours before starting this medicine. Sympatholytic agents may not completely prevent the increase in heart rate caused by this medicine, but they can generally prevent tachycardia. Patients receiving a β-blocker before starting treatment with this medicine typically have bradycardia; however, their heart rate is expected to increase to normal with this medicine. Concomitant administration of this medicine with a β-blocker or other sympatholytic agent generally results in little change in heart rate because their opposing effects on the heart counteract each other. Adjust the dose as appropriate according to age and symptoms.

Children's dosage

Children (12 years and younger): The initial dose is 0.2㎎/kg of body weight once daily. The dose may be increased by 50-100% until blood pressure is optimally controlled. The maintenance dose is 0.25㎎-1.0㎎/kg of body weight daily. A maximum of 50㎎ may be administered per day.

Precautions

This medication should not be used in certain patients. For example, patients with pheochromocytoma may be at risk due to increases in catecholamine, which can result from the antihypertensive effects of the drug. Additionally, it should not be administered to patients with pulmonary hypertension due to mitral stenosis, those who have had an acute myocardial infarction, or patients who have had previous allergic reactions to this medication. There are also patients who need to be cautious when using this drug, including those with chronic congestive heart failure, severe renal failure, angina, and those with hypersensitivity or allergic history to Yellow No. 4 (Tartrazine) contained in this drug. Possible side effects when using this drug include hirsutism, which can begin within 3 to 6 weeks after administration and usually appears on the face and body. Discontinuation of the drug will stop new hair growth, but it may take 1 to 6 months to return to the original state. Special attention should be given to children and women regarding this side effect. Other allergic symptoms reported include skin rashes, vesicles, and skin and mucosal syndrome. Blood tests may show decreased platelet or white blood cell counts, as well as changes in liver function test results. Changes in the electrocardiogram T-wave are often observed; however, these typically do not cause significant clinical problems and recover upon discontinuation of the drug. Pericardial effusion may rarely occur, especially in patients with poor renal function. In such cases, monitoring through echocardiography is necessary and additional treatment should be considered if needed. Other possible side effects include weight gain, peripheral vascular edema, increased heart rate, gastrointestinal disorders, breast pain, gynecomastia, anemia, headache, nausea, and vomiting. Generally, this drug is often used in conjunction with diuretics to prevent fluid retention and deterioration of heart failure. Weight and electrolyte status should be monitored regularly, and appropriate actions should be taken if abnormal symptoms arise. Moreover, because this medication dilates blood vessels and may reflexively increase heart rate, beta-blockers are sometimes co-administered to prevent this phenomenon. In patients with decreased renal function or those on dialysis, dosages of the drug should be adjusted, and it should only be used once the patient has stabilized after a myocardial infarction. During the initial treatment phase, regular evaluations such as urine tests, renal function tests, electrocardiograms, chest X-rays, and echocardiograms should be conducted to ensure safety. Caution is also necessary for interactions with other drugs. For example, concomitant use with guanethidine can result in severe hypotension, so guanethidine should be discontinued or this drug should only be started while the patient is hospitalized. Antidepressants or antipsychotics may also increase the risk of hypotension, and using corticosteroids or nonsteroidal anti-inflammatory drugs may lead to increased fluid retention, so caution is warranted. As the safety of this medication during pregnancy has not been established, it should be avoided, and during breastfeeding, it should be avoided if possible. If unavoidable, breastfeeding should be ceased. There is limited experience with the use of this drug in children, especially infants, so caution is advised. In case of overdose, severe hypotension may occur, requiring immediate medical treatment, including treatment for blood pressure maintenance and renal function protection. Sympathomimetics should be avoided as they may cause excessive heart stimulation.

Side effects

  • hair growth
  • thickening
  • pigmentation increase
  • exudative rash
  • vesicular lesions
  • mucous membrane syndrome
  • thrombocytopenia
  • leukopenia
  • decreased hematocrit
  • decreased hemoglobin
Show 21 more
  • decreased red blood cells
  • increased ALP
  • changes in ECG T wave
  • pericardial effusion
  • thromboembolism
  • peripheral vascular edema
  • increased heart rate
  • elevated creatinine
  • increased BUN
  • gastrointestinal disturbances
  • rash
  • mastalgia
  • gynecomastia
  • hemolytic anemia
  • pulmonary infiltration
  • increased antinuclear antibodies
  • headache
  • intermittent claudication
  • frequent menstruation
  • nausea
  • vomiting

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, at a temperature between 1°C and 30°C (room temperature). Storing it this way helps to maintain the effectiveness of the medication.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.